Dextroamphetamine
- Generic Name
- Dextroamphetamine
- Brand Names
- Adderall, Dexedrine, Mydayis, Procentra, Xelstrym, Zenzedi
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N
- CAS Number
- 51-64-9
- Unique Ingredient Identifier
- TZ47U051FI
- Background
Dextroamphetamine is the dextrorotary enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder.
- Indication
Dextroamphetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy
- Associated Therapies
- -
High doses of Adderall may increase psychosis risk
High-dose prescription amphetamine users face over five-fold increased risk of psychosis or mania, with 30 mg+ dextroamphetamine (40 mg Adderall) posing the highest risk, according to McLean Hospital research. The study, published in the American Journal of Psychiatry, highlights the need for dose consideration in prescribing stimulants, with 81% of psychosis or mania cases in high-dose users potentially preventable. No significant risk increase was observed with methylphenidate (Ritalin) use.
High Doses of ADHD Meds Could Trigger Psychosis
High doses of ADHD meds like Adderall can increase psychosis risk by over fivefold, with 30mg+ dextroamphetamine (40mg Adderall) posing the highest risk, according to a study in the American Journal of Psychiatry. Dr. Lauren Moran emphasizes dose as a critical factor in psychosis risk and suggests considering alternative ADHD treatments like methylphenidate (Ritalin), which showed no increased risk.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath